- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00209937
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
March 29, 2007 updated by: H. Lundbeck A/S
A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Active-Reference Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia
Study Overview
Detailed Description
To compare the hypnotic efficacy and safety of different dose levels of gaboxadol with placebo in non-elderly patients with primary insomnia over two weeks of treatment
Study Type
Interventional
Enrollment
675
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- diagnosis of Primary insomnia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety
|
Tolerability
|
Efficacy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Study Completion (ACTUAL)
June 1, 2004
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (ESTIMATE)
September 21, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
March 30, 2007
Last Update Submitted That Met QC Criteria
March 29, 2007
Last Verified
March 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- GABA Agents
- Anticonvulsants
- GABA Agonists
- Gaboxadol
Other Study ID Numbers
- 99775
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Insomnia
-
Midnight Pharma, LLCCompletedChronic Primary InsomniaUnited States
-
IWK Health CentreUnknownPrimary Insomnia | Nonorganic InsomniaCanada
-
Oregon Health and Science UniversityCompletedPrimary Insomnia | Psychophysiological InsomniaUnited States
-
University of RochesterSanofi-SynthelaboCompletedInsomnia | Primary Insomnia | Psychophysiologic InsomniaUnited States
-
US Department of Veterans AffairsCompletedInsomnia | Primary Insomnia | Secondary InsomniaUnited States
-
University of UtahEvans Army Community HospitalCompletedPrimary Insomnia | Secondary InsomniaUnited States
-
University of WashingtonUnknownChronic Insomnia | Insomnia, Primary
-
Jack Edinger, PhDMerck Sharp & Dohme LLCCompletedInsomnia | Primary Insomnia | Chronic InsomniaUnited States
-
University of PittsburghCompletedInsomnia Chronic | Insomnia, PrimaryUnited States
-
Eli Lilly and CompanyCompletedAn Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia (SLUMBER)Primary Insomnia | Secondary InsomniaUnited States
Clinical Trials on Gaboxadol
-
Ovid Therapeutics Inc.CompletedFragile X Syndrome (FXS)United States
-
Ovid Therapeutics Inc.TerminatedAngelman SyndromeUnited States, Israel
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompletedPrimary Insomnia
-
H. Lundbeck A/SWithdrawn
-
H. Lundbeck A/SCompletedShort-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderMajor Depressive DisorderAustria, Russian Federation
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/STerminated